VG111, A novel formulation (VG111) demonstrating clinical evidence of anti-pathogenic activity and accelerated wound healing in humans and companion animals

Abstract

Abstract VG111, a novel natural product formulation developed at PGIMER, Chandigarh is an attempt to meet the requirements of an ideal wound healing product. The present study demonstrates the efficacy of VG111 in antimicrobial assay, in tissue-regeneration,and in direct application-based wound healing. VG111 was able to kill major human pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli, carbapenem-resistant Acinetobacter baumannii (CRAB), while biofilm clearance was observed for Pseudomonas aeruginosa PA14 and Stenotrophomonas sepilia. Scratch assay and cytokine estimation in VG111-treated RAW464.7 cell lines show that it enhances cell migration and limits host inflammatory response by lowering IL-6 and TNF-α levels. VG111 application in canine and human patients’ representative cases provides evidence of remarkable wound healing and improved recovery. In particular, its potential to treat aggravated wounds in diabetic patients without the need of administering additional antibiotics in patients on steroids and obviating the need of skin graft adds on to make this natural product formulation to be a game-changer in the segment.